MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
In this research study, investigators will test whether prophylactic high-dose IV Mg
administration attenuates the risk of AKI in patients with malignant mesothelioma receiving
intraoperative chemotherapy (HIOC) with cisplatin compared to placebo
.
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH)